Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization.
OBJECTIVE
Osteopontin (OPN) is overexpressed in hepatocellular carcinoma (HCC) with postoperative recurrence or extrahepatic metastasis. However, its prognostic value in patients treated with transarterial chemoembolization (TACE) is unclear. We investigated the utility of serum OPN levels and changes therein as prognostic markers in HCC patients who have received TACE.


METHODS
Forty-six patients with HCC were enrolled. Serum OPN levels were measured before and 4 weeks after TACE. Serum biochemistry and computed tomography (CT) scans were analyzed. We evaluated baseline serum OPN levels and subsequent changes therein in relation to tumor responses and cumulative survival rates following TACE. A decreasing pattern was defined as a decrease after TACE of more than 10% relative to baseline levels. A "responder" was defined as a patient who exhibited a tumor necrosis rate of higher than 50% on the follow-up CT scan.


RESULTS
Higher initial serum OPN levels were associated with a large tumor, portal vein invasion, and an advanced tumor stage. Patients who had lower initial serum OPN levels and those who exhibited decreasing patterns after TACE tended to have more favorable tumor responses (P=0.043 and 0.055, respectively) and exhibited better cumulative survival rates (P=0.036 and 0.030, respectively). However, the initial serum OPN level and subsequent changes in serum OPN levels were not independent predictors for survival on multivariate analysis.


CONCLUSIONS
Serum OPN levels were significantly higher in patients with advanced HCC. In addition, HCC patients with low pretreatment serum OPN levels and those for whom serum OPN declined following TACE exhibited better tumor responses and survived for longer.
Kim
Sung Hoon
SH
Department of Internal Medicine, Seoul Veterans Hospital, Korea.
Chung
Young Hwa
YH
Yang
Soo Hyun
SH
Kim
Jeong A
JA
Jang
Myoung Kuk
MK
Kim
Sung Eun
SE
Lee
Danbi
D
Lee
Sae Hwan
SH
Lee
Don
D
Kim
Kang Mo
KM
Lim
Young Suk
YS
Lee
Han Chu
HC
Lee
Yung Sang
YS
Suh
Dong Jin
DJ
D000328:Adult; D000368:Aged; D019540:Area Under Curve; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000556:secondary / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D053495:Osteopontin / Q000097:blood*; D011169:Portal Vein / Q000473:pathology; D011379:Prognosis; D012720:Severity of Illness Index; D015996:Survival Rate; D014057:Tomography, X-Ray Computed
D053495:Osteopontin